Natural killer cell

Nkarta to Present at Upcoming Investor Conference

Retrieved on: 
Wednesday, June 16, 2021

SOUTH SAN FRANCISCO, Calif., June 16, 2021 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a biopharmaceutical company developing engineered natural killer (NK) cell therapies to treat cancer, today announced its participation at this upcoming investor conference:

Key Points: 
  • SOUTH SAN FRANCISCO, Calif., June 16, 2021 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a biopharmaceutical company developing engineered natural killer (NK) cell therapies to treat cancer, today announced its participation at this upcoming investor conference:
    The live webcast of the presentation will be available on the Investors section of Nkartas website, www.nkartatx.com .
  • A replay of the webcast will be archived on the website for approximately four weeks.
  • Nkarta is a clinical-stage biotechnology company advancing the development of allogeneic, off the shelf natural killer (NK) cell therapies for cancer.
  • For more information, please visit www.nkartatx.com .

Senti Bio Signs Lease Agreement and Begins Design of Clinical and Commercial-Scale Manufacturing Facility for Allogeneic CAR-NK Cell Therapies

Retrieved on: 
Tuesday, June 15, 2021

Senti Bio is designing the 92,000 square-foot facility to meet current Good Manufacturing Practices (cGMP) with the goal of providing clinical and commercial-scale manufacturing for multiple allogeneic, or off-the-shelf, chimeric antigen receptor (CAR) natural killer (NK) cell product candidates.

Key Points: 
  • Senti Bio is designing the 92,000 square-foot facility to meet current Good Manufacturing Practices (cGMP) with the goal of providing clinical and commercial-scale manufacturing for multiple allogeneic, or off-the-shelf, chimeric antigen receptor (CAR) natural killer (NK) cell product candidates.
  • Internal manufacturing capabilities are central to Senti Bios business strategy of maintaining control over the quality and supply of its present and future candidates for allogeneic CAR-NK cell therapies.
  • We believe that theapplication of next-generation allogeneic CAR-NK cell therapies has the potential to improve the lives of cancer patients who currently face limited treatment options.
  • SENTI-301 is a Multi-Armed allogeneic CAR-NK cell therapy candidate that is being designed to overcome disease evasion for the treatment of HCC.

William Sullivan, CPA, MBA joins Cytovia Therapeutics as Chief Financial Officer

Retrieved on: 
Tuesday, June 15, 2021

and AVENTURA, Fla., June 15, 2021 (GLOBE NEWSWIRE) -- Cytovia Therapeutics, Inc., a biopharmaceutical company developing allogeneic off-the-shelf gene-edited Chimeric Antigen Receptor (CAR)-NK cells derived from induced pluripotent stem cells (iPSCs) and NK cell engager multifunctional antibodies, announced today that William Sullivan, CPA, MBA has been appointed as Chief Financial Officer, effective immediately.

Key Points: 
  • and AVENTURA, Fla., June 15, 2021 (GLOBE NEWSWIRE) -- Cytovia Therapeutics, Inc., a biopharmaceutical company developing allogeneic off-the-shelf gene-edited Chimeric Antigen Receptor (CAR)-NK cells derived from induced pluripotent stem cells (iPSCs) and NK cell engager multifunctional antibodies, announced today that William Sullivan, CPA, MBA has been appointed as Chief Financial Officer, effective immediately.
  • We are delighted to welcome Bill as Chief Financial Officer of Cytovia as the company prepares to go public, added Dr. Daniel Teper, CEO of Cytovia Therapeutics.
  • Prior to joining Cytovia, he was Chief Financial Officer and Treasurer at Applied Genetic Technologies Corporation (AGTC), a publicly traded gene therapy company, where he led multiple financings and core business and finance functions.
  • Prior to AGTC, he worked at Merrimack Pharmaceuticals, Inc. for 10 years and held a variety of important leadership positions including Chief Financial Officer.

Global NK Cell Therapies Pipeline Market Report 2021 - ResearchAndMarkets.com

Retrieved on: 
Monday, June 14, 2021

The "NK Cell Therapies - Pipeline Insight, 2021" drug pipelines report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "NK Cell Therapies - Pipeline Insight, 2021" drug pipelines report has been added to ResearchAndMarkets.com's offering.
  • This "NK Cell therapy - Pipeline Insight, 2021," report provides comprehensive insights about 80+ companies and 100+ pipeline drugs in NK Cell therapy pipeline landscape.
  • The companies and academics are working to assess challenges and seek opportunities that could influence NK Cell therapy R&D.
  • The therapies under development are focused on novel approaches to treat/improve NK Cell therapy.

Nkarta Therapeutics CEO, Paul Hastings, Named BIO Chair for 2021-2022 Term

Retrieved on: 
Monday, June 14, 2021

He will serve as BIO chair through June 2022, when he will be eligible for re-election for another one-year term.

Key Points: 
  • He will serve as BIO chair through June 2022, when he will be eligible for re-election for another one-year term.
  • I look forward to working closely with Paul as our new Board Chair, said BIO President and CEO Dr. Michelle McMurry-Heath.
  • Paul has been an active and highly engaged leader of BIO for more than two decades.
  • Nkarta is a clinical-stage biotechnology company advancing the development of allogeneic, off-the-shelf natural killer (NK) cell therapies for cancer patients.

2021 Pipeline Insights on NK Cell Therapy - Featuring Nantkwest, Coronado Biosciences and Affimed Among Others - ResearchAndMarkets.com

Retrieved on: 
Thursday, June 10, 2021

The "NK Cell Therapy - Pipeline Insight, 2021" drug pipelines has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "NK Cell Therapy - Pipeline Insight, 2021" drug pipelines has been added to ResearchAndMarkets.com's offering.
  • This report provides comprehensive insights about 15+ companies and 15+ pipeline drugs in NK cell therapy pipeline landscape.
  • The companies which have their NK cell therapy drug candidates in the most advanced stage, i.e.
  • NK cell therapy pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration.

Innate Pharma Presents New Data on Next-Generation NK Cell Engager Platform at FOCIS 2021 Annual Meeting

Retrieved on: 
Thursday, June 10, 2021

This latest innovation leverages the advantages of harnessing NK cell effector functions against cancer cells and also provides proliferation and activation signals targeted to NK cells.

Key Points: 
  • This latest innovation leverages the advantages of harnessing NK cell effector functions against cancer cells and also provides proliferation and activation signals targeted to NK cells.
  • This data set is built on Innates existing tri-specific NK cell engager technology, which has demonstrated potent NK cell activation, cytotoxicity and efficient control of tumor growth in preclinical models.
  • We are excited to introduce the new evolution of our ANKET platform at the FOCIS meeting today, said Pr.
  • ANKET(Antibody-based NK cell Engager Therapeutics) is Innate Pharma's proprietary platform for developing next-generation, multi-specific NK cell engagers to treat certain types of cancer.

Shoreline Biosciences and BeiGene Announce Strategic Worldwide Collaboration to Develop and Commercialize Genetically Modified Natural Killer (NK) Cell Therapies

Retrieved on: 
Wednesday, June 9, 2021

In the multi-target collaboration, the companies have agreed to work jointly to develop cell therapies for four designated therapeutic targets, with an option to expand the collaboration at a future date.

Key Points: 
  • In the multi-target collaboration, the companies have agreed to work jointly to develop cell therapies for four designated therapeutic targets, with an option to expand the collaboration at a future date.
  • BeiGene will have commercial rights globally, with Shoreline having an option to retain U.S. and Canadian commercialization rights for two targets.
  • Shoreline has developed a proprietary platform focused on iPSC-derived natural killer (NK) cells and macrophages that are optimized with precise and rational genetic reprogramming.
  • The Shoreline NK cell and macrophage-based cell therapies are designed to provide an effective and efficient means for targeting and killing tumors as well as repairing tissue homeostasis.

Acepodia Publishes Preclinical Data on Novel Off-the-Shelf Natural Killer Cell Therapy, ACE1702, for HER2-Expressing Solid Tumors Using Antibody-Cell Conjugation Technology in the Journal Cancers

Retrieved on: 
Monday, June 7, 2021

The article, titled A Novel off-the-Shelf Trastuzumab-Armed NK Cell Therapy (ACE1702) Using Antibody-Cell-Conjugation Technology, is available on the Acepodia corporate website at Acepodia.com/newsroom/publications .

Key Points: 
  • The article, titled A Novel off-the-Shelf Trastuzumab-Armed NK Cell Therapy (ACE1702) Using Antibody-Cell-Conjugation Technology, is available on the Acepodia corporate website at Acepodia.com/newsroom/publications .
  • Data from this study reinforce the potential of ACE1702 as a potent and safe off-the-shelf therapy against HER2-expressing cancers.
  • Preclinical results demonstrate that trastuzumab conjugation by ACC technology provides oNK cells with specific and enhanced cytotoxicity against HER2-expressing cancer cells.
  • Its lead product candidate, ACE1702, is the first antibody-conjugated NK cell therapy in clinical development for the treatment of HER2-expressing solid tumors.

Sorrento and Researchers at Karolinska Institutet Have Signed a Research Collaboration Agreement on iPSC-Derived Dimeric Antigen Receptor-Modified Natural Killer (DAR-NK) Cells With The Vision to Bring “Off-The-Shelf" NK Cell-Based Cancer Treatments Rap

Retrieved on: 
Friday, June 4, 2021

Sorrento and KI are collaborative partners in the Competence Center for the development of next-generation NK cell-based cancer immunotherapies (NextGenNK) coordinated by KI.

Key Points: 
  • Sorrento and KI are collaborative partners in the Competence Center for the development of next-generation NK cell-based cancer immunotherapies (NextGenNK) coordinated by KI.
  • We are proud to contribute our technologiesto producenewoptimizedoff-the-shelf adoptive NK cell immunotherapies," said Dr.Henry Ji, Chairman and CEO of Sorrento.
  • Sorrento expects these validated re-engineered NK cell-based therapeutic candidates could potentially become a new generation in off-the-shelf treatments for cancer and infectious diseases.
  • The present collaboration brings together key competence from Sorrento and KI in an important area of cancer immunotherapy research.